Review
This review summarizes studies related to anti-angiogenic treatment, synthetic lethality, and checkpoint inhibition of ovarian cancer and additionally novel combinations that offer a veritable therapeutic matrix for clinicians to choose from.
Review
In the care of oncology patients, poly-ADP-ribose polymerase (PARP) inhibitors are best known as a semitargeted treatment
for BRCA1- and BRCA2-associated ovarian and breast cancers, this article reviews the broader understanding of PARP biology that has spurred interest in expanding their clinical utility.